Dr. Loic Lang-Lazdunski

About Dr. Loic Lang-Lazdunski

Accreditations: European Association for Cardio-Thoracic Surgery

European Society of Thoracic Surgeons

International Mesothelioma Interest Group

International Association for the Study of Lung Cancer
Fast Facts: Dr. Lang-Lazdunski’s most recent study included 150 consecutive mesothelioma patients who underwent aggressive pleurectomy and decortication surgery with no 30 or 90-day mortality.

His work contributed to the American Society of Clinical Oncology officially recommending radical surgery in its 2018 guideline for management of pleural mesothelioma.

Dr. Lang-Lazdunski also is a world-renowned expert on minimally invasive thoracic surgery and complex thoracic surgery for advanced lung cancer and mediastinal tumors.

Although he is recognized as one of the world’s foremost authorities on mesothelioma surgery, Dr. Loic Lang-Lazdunski believes it takes a specialty center with multidisciplinary expertise to treat the cancer optimally.

“It’s the collaboration with experts in all the fields that will make us successful with these patients,” he said. “It’s the personalization of the treatment and the extensive experience from pulmonologists, surgeons, oncologists, pathologists, anesthetists and nurses on staff.”

Lang-Lazdunski came to Quebec after 12 years as a consultant thoracic surgeon at Guy’s and St. Thomas’ NHS Foundation Trust in London. He became professor of thoracic surgery at King’s College, London, with a chair in mesothelioma in 2012.

His extensive experience in treating pleural mesothelioma — and his success — has led to an international following. He contributes regularly to the European Lung Cancer Congress, World Conference on Lung Cancer, International Mesothelioma Interest Group, American Society of Clinical Oncology and the European Society of Thoracic Surgeons.

Lang-Lazdunski collaborates with prominent specialists worldwide and has contributed several landmark studies that have helped improve both treatment and prognosis of pleural mesothelioma.